 7. The subject has stable blood pressure or has ongoing and stable treatment with an angiotensin converting-enzyme inhibitor ACEI or an angiotensin receptor blocker ARB initiated at least 8 weeks prior to renal biopsy. Treatment must be stable during the 6-week period immediately prior to NKA injection. Stable treatment is defined as dose adjustment no less than one-half of the current dosage and no more than 2 times the current dosage. Dose interruptions up to 7 days due to medical necessity are allowed. A subject who is intolerant or not currently on an ACEI or ARBs may be included as long as heshe has stable blood pressure within the specified limits. 